Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
MEDVi's advantages: 24/7 provider messaging, both injectable and oral options, and tirzepatide availability
Drug type Dual GIP/GLP-1 receptor agonist Active ingredient Tirzepatide (same as Zepbound/Mounjaro) FDA status Not FDA-approved (compounded) 2026 legality Narrow 503A patient-specific only Typical cost ~$125$449/mo, self-pay Looking for a prescription provider route
The breakthrough in semaglutide weight loss treatment brings new hope to many people
We used a clipping device to close the micro perforation
US$ 22.66
US$ 26.26
US$ 24.63
US$ 20.24
US$ 25.61
US$ 24.22
